Effect of timing of administration on lipid-lowering efficacy of statins-meta-analysis

被引:0
|
作者
Wang, Chang [1 ]
Quan, Yawen [2 ]
Wang, Linfeng [3 ]
Li, Gang [1 ,4 ]
机构
[1] North China Univ Sci & Technol, Grad Sch, Tangshan, Hebei, Peoples R China
[2] Hebei Med Univ, Grad Sch, Shijiazhuang, Hebei, Peoples R China
[3] Hebei North Univ, Grad Sch, Zhangjiakou, Hebei, Peoples R China
[4] Hebei Gen Hosp, Inst Geriatr Dis, Div Cardiol, Shijiazhuang 050000, Hebei, Peoples R China
基金
中国国家自然科学基金;
关键词
Statins; Low-density lipoprotein cholesterol; Cholesterol; Half-life; Duration of medication; Medication morning and evening; CONTROLLED-RELEASE SIMVASTATIN; OPTICAL COHERENCE TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; SERUM-CHOLESTEROL; EVENING INTAKE; DOUBLE-BLIND; SAFETY; ATORVASTATIN; RATIONALE; THERAPY;
D O I
10.1007/s00228-023-03575-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background To investigate the effect of timing of statin administration on lipid-lowering efficacy.Methods Computer searches of Pubmed, Embase, Cochrane Library, and Web of Science databases from 1986 to 2023. The impact of administration time on the lipid-lowering efficacy of statin drugs was investigated. Following a series of screenings, a funnel plot was constructed to assess its symmetry, and Egger and Beggar tests were conducted using StataMP-64 to evaluate publication bias. Meta-analysis was performed using RevMan 5.3 to combine MD values.Results Fifteen papers (1352 participants) met and included the criteria. The results of the meta-analysis showed that the effect of morning and evening administration time on plasma triglycerides (TG) (P > 0.05) and plasma high-density lipoprotein cholesterol (HDL-C) (P > 0.05) was not statistically significant. There were significant reductions in total cholesterol (TC) (MD: 0.15 mmol/L, 95% CI: 0.06-0.23, P < 0.01) and low-density lipoprotein cholesterol (LDL-C) (MD: 0.10 mmol/L, 95% CI: - 0.00-0.20, P < 0.01) in the night group. According to the analysis results of the half-life of statins, only short half-life statins showed that nocturnal administration reduced LDL-C (MD: 0.21 mmol/L, 95% CI: 0.09-0.33, P < 0.01) and TC (MD: 0.32 mmol/L, 95% CI: 0.18-0.46, P < 0.01) levels and was better than morning administration. Long half-life statins did not show significant differences. In addition, the administration time of short half-life statins also showed that night administration tended to reduce TG (MD: 0.16 mmol/L, 95% CI: 0.02-0.30, P < 0.05) levels. In subgroup analysis according to clinical factors in patients aged < 55 years, there was no significant difference in the timing of administration between the two groups; the efficacy of statins in lowering lipids in patients aged >= 55 years was significantly different in the TC group (P < 0.01) and LDL-C group (P < 0.01). The administration time of the TC group (P < 0.05) and LDL-C group (P < 0.05) in the Americas, Europe, and Asian groups was significantly different for statins. In addition, the American group also showed that the administration time of the two groups was significantly different from the TG group (P < 0.05).Conclusion The efficacy of administering short half-life statin drugs at night in reducing plasma levels of TC, LDL-C, and TG surpasses that of morning administration. However, this study did not determine the impact of timing of statin administration in patients taking long half-life statins on the efficacy of the medication. Therefore, it is recommended to consider patient adherence when. The study was registered on PROSPERO (International Prospective Register of Systematic Reviews) as CRD42022372105 (available at https://www.crd.york.ac.uk/prospero/).
引用
收藏
页码:1641 / 1656
页数:16
相关论文
共 50 条
  • [1] Effect of timing of administration on lipid-lowering efficacy of statins-meta-analysis
    Chang Wang
    Yawen Quan
    Linfeng Wang
    Gang Li
    European Journal of Clinical Pharmacology, 2023, 79 : 1641 - 1656
  • [2] Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis
    Dykun, Iryna
    Mincu, Raluca
    Hendricks, Stefanie
    Balcer, Bastian
    Totzeck, Matthias
    Rassaf, Tienush
    Mahabadi, Amir A.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (15) : 1675 - 1678
  • [3] Lipid-lowering efficacy of rosuvastatin compared with other statins
    Meshkov, A. N.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2012, 8 (05) : 691 - 693
  • [4] Statins and Lipid-Lowering Strategies in PD
    Heimburger, Olof
    PERITONEAL DIALYSIS - STATE-OF-THE-ART 2012, 2012, 178 : 106 - 110
  • [5] Lipid-lowering with statins and fibrinolytic parameters
    Jovin, IS
    Heidinger, K
    Taborski, U
    MullerBerghaus, G
    EUROPEAN HEART JOURNAL, 1997, 18 (09) : 1516 - 1516
  • [6] Lipid-Lowering Efficacy of Red Yeast Rice in a Population Intolerant to Statins
    Venero, Carmelo V.
    Venero, Jose V.
    Wortham, Dale C.
    Thompson, Paul D.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (05): : 664 - 666
  • [7] Lipid-lowering drugs and homocysteine - A comparison between statins and other lipid-lowering drugs
    Jankowski, P
    Kawecka-Jaszcz, K
    ATHEROSCLEROSIS, 2004, 172 (01) : 191 - 194
  • [8] EFFICACY OF INTENSIVE LIPID-LOWERING THERAPY AFTER CABG: A META-ANALYSIS
    Soliman, Youssef
    Mouffkes, Adel
    ATHEROSCLEROSIS, 2024, 399
  • [9] Update on statins and other lipid-lowering drugs
    Miller, CA
    GERIATRIC NURSING, 2001, 22 (05) : 276 - 277
  • [10] Hepatotoxicity of statins and other lipid-lowering agents
    Bjornsson, Einar S.
    LIVER INTERNATIONAL, 2017, 37 (02) : 173 - 178